Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis

Clinical Chemistry

Volumn 56, Issue 3, 2010, Pages 391-398

  Algeciras Schimnich, Alicia ^a   Milosevic, Dragana ^a   McIver, Bryan ^a   Flynn, Heather ^a   Reddi, Honey V ^a   Eberhardt, Norman L ^a   Grebe, Stefan K G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR PAX8;

ADULT; ARTICLE; ASPIRATION BIOPSY; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FROZEN SECTION; GENE FUSION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID NODULE;

ADENOCARCINOMA, FOLLICULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 77649228521     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.134015     Document Type: Article

References (20)

1. Weber F, Eng C. Gene-expression profiling in differentiated thyroid cancer - a viable strategy for the practice of genomic medicine? Future Oncol 2005;1:497-510.
2. Eszlinger M, Krohn K, Hauptmann S, Dralle H, Giordano TJ, Paschke R. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J Clin Endocrinol Metab 2008;93:3286 -94.
3. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, et al. RAS point mutations and PAX8-PPARγrearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003;88:2318 -26.
4. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990;4:1474 -9.
5. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003;88:2745-52.
6. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289:1357- 60.
7. McIver B, Grebe SK, Eberhardt NL. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:221-34.
8. Powell JG, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, et al. The PAX8/ PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wildtype PPARγ inhibition. Oncogene 2004;23:3634-41.
9. WAF1/CIP1. Oncogene 2006;25:2304 -17.
10. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002;26: 1016-23.
11. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, et al. PPARγ staining as a surrogate for PAX8/ PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 2005;90:463- 8.
12. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003;88: 4440 -5.
13. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V. Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002;87:3947-52.
14. Reddi HV, McIver B, Grebe SK, Eberhardt NL. The paired box-8/peroxisome proliferator-activated receptor-γ oncogene in thyroid tumorigenesis. Endocrinology 2007;148:932-5.
15. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. 3rd ed. New York: Garland Publishing; 1994.
16. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092- 8.
17. Hemmer S, Wasenius VM, Knuutila S, Joensuu H, Franssila K. Comparison of benign and malignant follicular thyroid tumours by comparative genomic hybridization. Br J Cancer 1998;78: 1012-7.
18. Johannessen JV, Sobrinho-Simoes M, Lindmo T, Tangen KO. The diagnostic value of flow cytometric DNA measurements in selected disorders of the human thyroid. Am J Clin Pathol 1982;77:20-5.
19. Schelfhout LJ, Cornelisse CJ, Goslings BM, Hamming JF, Kuipers-Dijkshoorn NJ, van de Velde CJ, Fleuren GJ. Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms. Int J Cancer 1990;45:16 -20.
20. Castro P, Eknaes M, Teixeira MR, Danielsen HE, Soares P, Lothe RA, Sobrinho-Simoes M. Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol 2005;206:305-11.